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between serum ADCC titer and the stage of HIV-related illness as determined by T-helper-cell numbers. These experiments clearly implicated gp160 as the target antigen of HIV-specific ADCC activity following natural infection. Vaccines which stimulate antibodies directed against gpl60, which are capable of mediating ADCC against infected cells, could be important for protection against infection by cell-associated virus.
The acquired immunodeficiency syndrome is the ultimate result of infection with the human retrovirus human immunodeficiency virus (HIV) (15) . Natural infection with this virus usually occurs after contact with infected blood or genital secretions (15) , both of which are lymphocyte-containing fluids. Recent evidence suggests that semen contains both monocytes/macrophages and CD4+ lymphocytes which could be infected with HIV (29) , indicating the possible importance of cell-associated virus in HIV transmission.
One hypothesized method by which the body can protect itself against cell-associated virus invasion is by the action of antibodies which mediate antibody-dependent cell-mediated cytotoxicity (ADCC), in which cells expressing appropriate viral antigens are lysed, in a non-major histocompatibility complex-restricted manner, in the presence of antibodies and killer cells (8) . Considering the probable contribution of cell-associated HIV to disease transmission, potential vaccines should be able to stimulate antibodies capable of mediating ADCC against infected cells, in order to offer maximum host protection.
It has recently been shown that high titers of HIV-specific ADCC antibodies can be found in sera from HIV-antibodypositive individuals (2, 10, 16, 21) , but whether this antibody is predominantly directed against p55/p24/pl7 (gag) or gp120/gp41 (envelope) determinants remains controversial.
Vaccinia virus (VV) vectors have been used successfully to express foreign viral proteins in target cells and have been instrumental in delineating target antigens of virus-specific cytotoxic T lymphocytes in HIV (26) and other virus (12) infections. A recent report indicates that VV vectors can also be used successfully in HIV-specific ADCC assays (23) . In the present study we used a series of VV vectors to * Corresponding author. express proteins from the envelope and gag genes of HIV to delineate the target antigens of HIV-specific ADCC antibodies in the sera of HIV-infected hemophiliacs. In addition, we attempted to correlate these ADCC responses with other known prognostic indicators of HIV disease progression.
MATERIALS AND METHODS Sera. Samples were obtained from the extensive serum bank which is maintained for sera of approximately 150 hemophilia patients as part of an ongoing study of immunoregulatory defects in hemophilia (25) . All samples were maintained at -80°C and were heat inactivated for 30 min at 56°C prior to assay. HIV serology was determined by Western blot (immunoblot).
Lymphocyte separation. Peripheral blood mononuclear cells (PBMCs) from healthy HIV-seronegative laboratory controls (for ADCC assay) or hemophilia patients (for surface marker analysis) were isolated from freshly drawn heparinized venous blood by centrifugation on Ficoll-Paque (Pharmacia Fine Chemicals, Piscataway, N.J.) density gradients (25) . PBMC preparations contained 70 to 80% lymphocytes, 10 In all HIV-seropositive sera tested, ADCC reacting against targets expressing HIV surface protein and transmembrane protein was present at greater serum dilutions than ADCC reacting against NYCBH-infected targets, allowing for a clear delineation of these two activities. Indeed, in more than 80% of these sera, the difference was present at a serum dilution of 1/1,000. No ADCC against gpl60 above that observed against VV could be demonstrated in HIV-seronegative sera. Representative data for three sera are presented in Fig. 1 and demonstrate HIV gpl60-specific ADCC at a serum dilution of 1/1,000 or greater, whereas VV-or EBV-specific ADCC was absent at similar serum dilutions. In all further experiments, sera with greater than 20% ADCC against NYCBH-infected targets at a serum dilution of 1/1,000 were discarded (<15% of sera tested).
NK cells bearing a CD16 phenotype are known to mediate in vitro ADCC responses (8) . The HIV envelope glycoprotein-specific ADCC demonstrated by the results in Fig. 1 was shown to be K-cell mediated, as evidenced by inhibition of killing after Leullb-directed complement-mediated depletion of effector cells (Table 2) .
Having determined that gpl60-specific ADCC was detectable with VV vector-infected targets and that the optimum serum dilution was approximately 1/1,000, we assayed sera from 19 hemophilia patients (6 HIV seronegative, 7 HIV seropositive with normal numbers of T helper cells, and 6 HIV seropositive with decreased numbers of T for their ability to mediate HIV envelope-or gag-specific ADCC at a serum dilution of 1/1,000. Of the 13 HIVseropositive sera tested, 12 had antibodies to p55, 10 had antibodies to p24, 5 had antibodies to p17, and all 13 had antibodies to gp4l and gpl20 by Western blot. HIV envelope-specific ADCC activity could be demonstrated at a serum dilution of 1/1,000 in all 13 HIV-seropositive sera tested. None of these sera, however, were capable of mediating HIV gag-specific ADCC against targets expressing processed or unprocessed gag antigens at the same dilution. The six HIV-seronegative sera failed to mediate ADCC against targets expressing envelope or gag antigens. Cumulative data for these 19 sera are shown in Fig. 2 and clearly demonstrate that the HIV-seropositive sera contained a statistically significant (P < 0.01) ADCC activity against envelope-expressing targets compared with that against VV-or gag-expressing targets. near-normal (>400/,ul) numbers of T helper cells and those with severely decreased (<200/,ul) numbers of T helper cells.
To determine whether the absence of HIV gag-directed ADCC in HIV-seropositive sera was a result of assaying nonoptimal serum dilutions, eight HIV-seropositive sera were assayed over a range of serum dilutions. All eight sera tested, regardless of maximum cytolysis, showed optimum envelope-specific ADCC at a serum dilution of 1/1,000. No HIV gag-specific ADCC was demonstrable in any of the eight sera tested over a range of serum dilutions from 1/10 through 1/100,000 (Fig. 3) . Subsequent experiments performed at higher effector cell-to-target cell ratios (up to 100 to 1) and longer incubation times (up to 12 h) also failed to demonstrate gag-specific ADCC in any HIV-seropositive serum tested (data not shown).
The HIV envelope-specific ADCC titers of four sera from HIV-seropositive hemophiliacs with near-normal numbers of T helper cells and four sera from HIV-seropositive hemophiliacs with very low numbers of T helper cells were determined at half-log dilutions to establish whether ADCC titer varied between these two groups of patients. HIV ADCC titer was defined as the greatest serum dilution which was capable of mediating ADCC against vAbT 140-infected targets greater than two standard deviations above the mean ADCC against NYCBH-infected targets for all sera assayed at that dilution on a given day. By using this system, it was found that even patients with severe T-helper-cell depletions maintained high-titer serum HIV-specific ADCC activity and no difference in titer could be demonstrated between the two groups (Table 3) . DISCUSSION ADCC has been shown to be of prognostic importance in certain viral systems, particularly in chronic or transforming virus infections. Antibodies to EBV antigens which mediate ADCC have been shown to be of prognostic importance in Burkitt's lymphoma and nasopharyngeal carcinoma (18, 19 In addition, human T-cell lymphotropic virus type I (HTLV-I)-specific ADCC antibodies have been demonstrated in HTLV-I-infected individuals and have been correlated with the presence or absence of adult T-cell leukemia (13) . HIV-specific ADCC activity in the sera of infected individuals has been described (2, 10, 16, 21) , and the present study was undertaken to determine the antigenic specificity of these ADCC antibodies. Recombinant VV vectors expressing foreign viral genes have been valuable tools in defining immune responses in HIV and other viral infections (12, 26) and were chosen for use in this study for four reasons. First, HIV is known to infect B cells and EBVtransformed B-lymphoblastoid cell lines (B-LCLs), allowing the assay results to have some relevance to in vivo infection (6) . Second, the use of recombinant VVs expressing HIV genes allows us to present individual HIV proteins in infected cells. Third, B-LCLs infected with VV vectors expressing foreign viral proteins have been used with great success in defining the antigenic specificity of virus-specific cytotoxic T-lymphocyte responses after HIV (26) and other viral (12) infections, and as a result these cells are known to be relatively resistant to NK cell lysis in the absence of antibody. Fourth, HIV envelope-specific ADCC is known to be measurable with VV vectors expressing this glycoprotein (23) .
Since the majority of the hemophilia patients tested had antibodies to EBV or VV or both and these viral antigens were present in the recombinant VV vector-infected B-LCL target cells, the possibility existed that serum HIV-specifir ADCC activity would be obscured by VV-or EBV-specific responses. In our screening, however, we found that serum HIV-specific ADCC was always present at higher titers than ADCC activity against uninfected or VV-infected B-LCL targets. In more than 85% of the sera tested a clear difference in ADCC against NYCBH-infected targets compared with that against vAbT 140-infected targets was demonstrable at a serum dilution of 1/1,000. The low titer of VV-specific ADCC noted in this hemophiliac population was not unexpected since smallpox vaccination represents a remote viral infection and as a result ADCC titers to this virus have declined, whereas HIV represents an ongoing infection with stimulation of high-titer HIV-specific ADCC antibody responses. In addition, it is known that EBV-transformed B-LCLs are latently infected with EBV and do not have surface expression of membrane antigens responsible for EBV-specific ADCC (1).
We (4) , and the end products become situated in the outer cell membrane in a manner which allows for spontaneous syncytia formation in the presence of CD4-bearing cells (26) . As such, this viral product appears to be presented in much the same manner as it would be in HIV-infected cells. Less is known, however, about the natural presentation of gag antigens in HIV-infected cells. It has been suggested that the p17 product of the gag gene may actually protrude through the surface of the intact virion (22) , and therefore it could be postulated that p17 may protrude through the surface of the cell membrane during the process of viral budding and as a result be a target antigen of ADCC. Our inability to detect ADCC activity against cells In conclusion, the present study demonstrates that VV vectors expressing foreign viral proteins, which have been used with great success in elucidating cellular immune responses to virus infection, can also be used to delineate combined humoral and cellular immune responses to virus infection in the form of ADCC. This study clearly identified the envelope glycoprotein complex gpl20/gp41 as a major target antigen of HIV-specific ADCC antibodies and established that these antibodies were present at high titer and remained at high titer even in advanced stages of disease.
Although we were unable to demonstrate gag antigens as targets for ADCC antibodies in our system, the differences between antigen presentation in vector-infected and HIVinfected cells does not allow us to rule these out as possible target antigens of HIV-specific ADCC in some HIV-infected cells.
